Home
About
Issues
The Roundtable
Submissions
Contact
More
""Some conditions occur so infrequently that the cost of developing and bringing to the market a medicinal product to diagnose, prevent or treat the condition would not be recovered by the expected sales of the medicinal product; the pharmaceutical industry would be unwilling to develop the medicinal product under normal market conditions; these medical products are called 'orphan' "
In this article, Julie McNamara provides a rigorous analysis into the role of Regulation 141/2000/EC in incentivising the research and development of orphan medicinal products in the EU""
— Name, Title
BACK TO TOP
